Tritoqualine - OSE Immunotherapeutics

Drug Profile

Tritoqualine - OSE Immunotherapeutics

Alternative Names: OSE-1101

Latest Information Update: 26 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Unknown
  • Developer OSE Immunotherapeutics
  • Class Anti-inflammatories; Antiallergics; Antipruritics; Hepatoprotectants; Isoquinolines; Small molecules
  • Mechanism of Action Histamine H4 receptor agonists; Interleukin-8 expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Suspended Cystic fibrosis

Most Recent Events

  • 26 Sep 2016 Chemical structure information added
  • 31 May 2016 Effimune has merged with OSE Pharma to form OSE Immunotherapeutics
  • 24 Jun 2015 Suspended - Phase-I for Cystic fibrosis in France (unspecified route) (OSE Pharma Coverage Initiation Report, June 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top